Top Medical News
Exposure to statins may lower the risk of hepatic decompensation and mortality, as well as reduce portal hypertension, in patients with chronic liver diseases (CLDs), according to a systematic review and meta-analysis.
Audrey Abella, 2 days ago
The minimally invasive laparoscopic liver resection (LLR) appears to be a safe and feasible alternative to open liver resection (OLR) for patients with liver metastasis from colorectal cancer (CRC), according to a study.
Jairia Dela Cruz, 11 days ago
A genetic variant in the tolloid like 1 (TLL1) gene is strongly associated with the development of hepatocellular carcinoma (HCC) after the eradication of hepatitis C virus (HCV) infection by interferon-based therapy, according to a genome-wide association (GWAS) study.
Jairia Dela Cruz, 16 days ago
Adolescent males with a high body mass index (BMI) appear to be at a greater risk of severe liver disease including hepatocellular carcinoma (HCC), and this risk is more pronounced in men who develop type 2 diabetes mellitus (T2DM), according to a population-based cohort study.
Saras Ramiya, one month ago
The first NGO joint forum at the Asian Pacific Association for Study of the Liver (APASL) conference recently aims to build collaboration in support of national hepatitis policymaking and service delivery.
Audrey Abella, one month ago
Hormone replacement therapy (HRT), but not oral contraceptives (OC), could lead to the development of gallstones, a recent study has found.
one month ago
Adjuvant adoptive immunotherapy (AIT) for hepatocellular carcinoma (HCC) patients who have received therapy is both safe and effective for improving mortality rates and tumour recurrence, a new meta-analysis shows.
Special Reports
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
09 Nov 2016
At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.
26 Sep 2016
In this edition of MIMS Hepatology, we bring you recent updates in the treatment of hepatitis C, as well as highlights from two lectures presented in conjunction with the launch of Harvoni® (ledipasvir/sofosbuvir; LF Asia). 
30 Oct 2015
VIEKIRA PAK– ombitasvir, paritaprevir, ritonavir 12.5/7.5/50 mg tab copackaged with dasabuvir 250 mg film-coated tab,an innovative treatment for genotype 1 chronic hepatitis C.
03 Sep 2015
At a recent Abbott-sponsored symposium during the 11th Liver Update 2015, Professor José Mato discussed the role of S-adenosylmethionine (SAMe) in liver diseases. The following are highlights from his talk.
03 Sep 2015
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors. 
Conference Reports
Pearl Toh, 09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Pearl Toh, 08 Mar 2017
Add-on of pegylated interferon (pegIFN) to nucleos(t)ide analogues (NA) therapy may be a better strategy than a switch from NA to pegIFN in patients with chronic hepatitis B (CHB) who are on long-term NA therapy, according to data from an interim analysis of the SWAP* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.
Tristan Manalac, 25 Feb 2017
Compared with viral hepatocellular carcinomas and those of other aetiologies, cryptogenic hepatocellular carcinomas tend to manifest at later stages and are associated with worse survival, according to a study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017).
Pearl Toh, 24 Feb 2017
The goal of treatment for portal hypertension varies depending on the different stages and substages of cirrhosis, and hence, pharmacological therapies for managing portal hypertension should be considered in the context of other complications of cirrhosis, according to a presentation at the recent APASL 2017 held in Shanghai, China recently.
24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Roshini Claire Anthony, 23 Feb 2017

The use of statins is associated with a lower risk of pyogenic liver abscess, according to a Taiwan population-based case-control study. 

Elaine Soliven, 23 Feb 2017

Statin therapy may reduce the risk of cirrhosis and its associated comorbidities in chronic hepatitis B (CHB) patients, according to a presentation at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2017 held in Shanghai, China.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!